Cartilage intermediate layer protein (CILP) in cardiac fibrosis: Protective or pathogenic?

Area of Science:

• Cardiovascular Biology
• Fibrosis Research
• Extracellular Matrix Biology

Background:

• Heart failure (HF) is linked to cardiac fibrosis, excessive extracellular matrix (ECM) deposition by cardiac fibroblasts.
• Cartilage intermediate layer protein (CILP), a matricellular protein found in cardiac fibroblasts, is associated with cardiac fibrosis.
• CILP's role in cardiac tissue is unclear, with conflicting evidence on its protective or pathogenic functions despite its link to transforming growth factor beta (TGF-β).

Purpose of the Study:

• To review current knowledge on CILP in cardiac tissue.
• To explore CILP's relationship with cardiac fibroblast subpopulations.
• To evaluate CILP's potential as a biomarker and therapeutic target for cardiac fibrosis.

Main Methods:

• Literature review of existing studies on CILP in cardiac fibrosis.
• Analysis of CILP's regulation by TGF-β in cardiac and cartilage cells.
• Examination of CILP's association with cardiovascular and cardiometabolic disorders.

Main Results:

• CILP expression is promoted by TGF-β in cardiac fibroblasts and chondrocytes.
• Conflicting evidence exists regarding CILP's role: potentially protective by inhibiting TGF-β signaling or pathogenic by promoting fibrosis.
• Elevated circulating CILP levels are observed in patients with cardiovascular or cardiometabolic disorders, suggesting biomarker potential.

Conclusions:

• CILP's precise function in cardiac fibrosis remains ambiguous.
• Further research is needed to clarify CILP's dual role and its interaction with cardiac fibroblast subpopulations.
• CILP presents potential as both a biomarker for HF and a therapeutic target for cardiac fibrosis.